|LETTER TO EDITOR
|Year : 2004 | Volume
| Issue : 4 | Page : 246-247
Dexamethasone cyclophosphamide pulse therapy: Some suggestions for modifications
Vijay Gandhi , SN Bhattacharya
Department of Dermatology and Venereology, University College of Medical Sciences and GTB Hospital, India
A-242, Surya Nagar, Ghaziabad - 201011, India
|How to cite this article:|
Gandhi V, Bhattacharya S N. Dexamethasone cyclophosphamide pulse therapy: Some suggestions for modifications. Indian J Dermatol Venereol Leprol 2004;70:246-7
|How to cite this URL:|
Gandhi V, Bhattacharya S N. Dexamethasone cyclophosphamide pulse therapy: Some suggestions for modifications. Indian J Dermatol Venereol Leprol [serial online] 2004 [cited 2020 May 28];70:246-7. Available from: http://www.ijdvl.com/text.asp?2004/70/4/246/12368
It was truly enlightening and educative reading the editorial on dexamethasone pulse therapy in dermatology and the associated viewpoint by Prof. Pasricha who is widely regarded as the father of pulse therapy in India. Pulse therapy has altered the management and outcome of autoimmune diseases in general and pemphigus in particular. It has slowly but surely replaced the conventional dosing schedules for administration of oral steroids. In response to Dr. Ramam's query (where do we go from here?), I would like to propose the following suggestions for modifications in the time tested though somewhat rigid protocol of pulse therapy:
1. The total duration of treatment may be individualized according to the severity of the disease and response to therapy. So instead of a regimental approach of a total of 18 months for phases II and III, we may rely on a combination of the clinical severity index, immunofluorescence titers and promptness of response to therapy to decide whether to shorten the duration in quick responders and to extend it in slow responders and smoldering cases.
2. The decision to stop pulse therapy after 18 months in phase II + III can be individualized depending on the results of immunofluorescence (IF) tests. This may decrease the relapse rates. The relapse rate is 13-27% if direct IF (DIF) is negative at the end of treatment but increases to 4-100% if DIF is positive. Similarly, the relapse rate is 24% if indirect IF (IIF) is negative and increases to 57% if IIF is positive at the end of treatment.,,
3. Serology by IIF can be replaced by ELISA for direct measurement of desmoglein 1 and desmoglein 3 antibodies.
4. As regards the reservations about the toxicity of cyclophosphamide, it is the cumulative dose that increases the chances of malignancies be it carcinoma of the bladder or hematological malignancies., A mathematical calculation shows that with a daily dose of cyclophosphamide of 50 mg in phases II and III, the cumulative dose is approximately 25 g. A simple approach to reduce the cumulative dose of cyclophosphamide would be to omit daily administration altogether and replace it with a bolus dose of 500 mg every 4 weeks. The modified phase II would then consist of bolus doses of dexamethasone (100 mg x 3 days) and cyclophosphamide (500 mg on day 2) for 9 months. The modified phase III would consist of only bolus doses of cyclophosphamide 500 mg intravenously every 4 weeks for a further 9 months instead of an oral dose of 50 mg daily. This would reduce the cumulative dose of cyclophosphamide in phases II and III to 9 g only.
5. The bladder toxicity with bolus doses of cyclophosphamide can be further reduced by concomitant administration of MESNA (sodium 2-mercaptoethane sulfonate) given intravenously. This is easily available in India and is given on the day of administration of bolus cyclophosphamide. The usual dose is equivalent to the dose of cyclophosphamide and is given intravenously over 15-30 minute infusions in 5 divided doses over 24 hrs. It acts by binding to the acrolein metabolite which is implicated in causing hemorrhagic cystitis and the subsequent development of transitional cell carcinoma of the bladder.
6. Regarding the management of patients with fulminant disease in whom activity is not controlled in spite of addition of interval pulses and daily steroids, a different approach may be the use of immunoablative high dose cyclophosphamide without stem cell rescue. This approach has been utilized with success in other autoimmune diseases like systemic lupus erythematosus, acquired aplastic anemia and more recently for paraneoplastic pemphigus.,, It involves use of a high dose of cyclophosphamide (50 mg/kg) intravenously to induce suppression of a clonal population of B cells followed by administration of granulocyte colony stimulating factor (G-CSF). A high dose of cyclophosphamide spares the progenitor hematopoeitic stem cells in the bone marrow which express high levels of aldehyde dehydrogenase, an enzyme causing resistance to cyclophosphamide. However, peripheral lymphoid tissue, being susceptible, is suppressed, with apparent clearing of pre-existing autoimmunity. After a nadir of leucopenia at 8-12 days, there is a repopulation by division of stem cells from the bone marrow which have been spared. G-CSF given during this period hastens this process. Obviously, this approach has to be reserved for severe cases unresponsive to conventional DCP and has to be carried out in institutional settings under cover of broad spectrum antibiotics and anti-candidal drugs. As G-CSF is now available in India (Grastim©) this approach can be tried in selected cases.
7. Persistent oral ulcers are usually treated with topical steroids in a gel/orabase. An alternative approach may be to spray these lesions directly with a steroid inhaler (budesonide or fluocinolone acetonide) used in asthma. Apart from a rapid effect, an additional advantage is that palatal and pharyngeal ulcers that are not accessible to topical steroids can be treated effectively.
I hope that the practicability of these suggestions can be tried in different centers in order to further improve the efficacy of pulse therapy.
| References|| |
|1.||Ramam M. Dexamethasone pulse therapy in Dermatology. Indian J Dermatol Venereol Leprol 2003;69:319-22. |
|2.||Pasricha JS. Pulse therapy as a cure for autoimmune diseases. Indian J Dermatol Venereol Leprol 2003;69:323-8. |
|3.||David M, Weissman-Katzendson V, Ben chetrit A, et al. The usefulness of immunofluorescent tests in pemphigus patients in clinical remission. Br J Dermatol 1989;120:391-5. |
|4.||Ratnam KV, Pang BK. Pemphigus in remission: Value of negative direct immunofluoresence in management. J Am Acad Dermatol 1994;30:547-50. [PUBMED] |
|5.||Harman KE, Albert S, Black MM; British Association of Dermatologists. Guidelines for the management of Pemphigus vulgaris. Br J Dermatol 2003;149:926-37. [PUBMED] [FULLTEXT]|
|6.||Radis C, Kahl L, Baker G, Wasko MC, Cash JM, Gallatin A, et al. Effects of cyclophosphamide on the development of malignancy and on long term survival of patients with rheumatoid arthritis. Arthritis Rheumatol 1995:38:1120-7. |
|7.||Talar Williams C, Hijazi Y, Walther M, Linehan WM, Hallahan CW, Lubensky I, et al. Cyclophosphamide induced cystitis and bladder cancer in patients with Wegener's granulomatosis. Ann Intern Med 1996:124:477-84. |
|8.||Brodsky RA, Sensenbrenher LL, Jones RJ. Complete remission in severe aplastic anemia after high dose cyclophophamide without marrow transplantation. Blood 1996;87:491-4. |
|9.||Brodsky RA, Petri M, Smith BD, Seifter EJ, Spivak JL, Styler M, et al. Immunoablative high dose cyclophosphamide without stem cell rescue for refractorysevere autoimmune disease. Ann Intern Med 1998;129:1031-5. [PUBMED] [FULLTEXT]|
|10.||Nousari HC, Brodsky RA, Jones RJ, Grever MR, Anhalt GJ. Immunoablative high dose cyclophosphamide without stem cell rescue in paraneoplastic pemphigus: Report of a case and review of this new therapy for severe autoimmune disease. J Am Acad Dermatol 1999:40:750-4. |